Cerus Gross Margin 2010-2024 | CERS
Current and historical gross margin for Cerus (CERS) over the last 10 years. The current gross profit margin for Cerus as of September 30, 2024 is %.
| Cerus Gross Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Gross Profit | Gross Margin |
| 2024-09-30 | $0.20B | $0.12B | 60.61% |
| 2024-06-30 | $0.19B | $0.12B | 60.82% |
| 2024-03-31 | $0.19B | $0.12B | 61.78% |
| 2023-12-31 | $0.19B | $0.12B | 62.90% |
| 2023-09-30 | $0.18B | $0.12B | 63.04% |
| 2023-06-30 | $0.18B | $0.12B | 63.39% |
| 2023-03-31 | $0.18B | $0.11B | 62.30% |
| 2022-12-31 | $0.19B | $0.11B | 60.64% |
| 2022-09-30 | $0.19B | $0.11B | 60.43% |
| 2022-06-30 | $0.18B | $0.11B | 59.56% |
| 2022-03-31 | $0.17B | $0.10B | 59.54% |
| 2021-12-31 | $0.16B | $0.10B | 60.00% |
| 2021-09-30 | $0.14B | $0.09B | 59.72% |
| 2021-06-30 | $0.13B | $0.08B | 60.31% |
| 2021-03-31 | $0.12B | $0.07B | 61.67% |
| 2020-12-31 | $0.12B | $0.07B | 62.61% |
| 2020-09-30 | $0.11B | $0.07B | 63.55% |
| 2020-06-30 | $0.10B | $0.07B | 64.36% |
| 2020-03-31 | $0.10B | $0.06B | 64.58% |
| 2019-12-31 | $0.09B | $0.06B | 64.52% |
| 2019-09-30 | $0.09B | $0.06B | 63.22% |
| 2019-06-30 | $0.08B | $0.05B | 61.45% |
| 2019-03-31 | $0.08B | $0.05B | 61.25% |
| 2018-12-31 | $0.08B | $0.05B | 60.00% |
| 2018-09-30 | $0.07B | $0.04B | 56.76% |
| 2018-06-30 | $0.07B | $0.04B | 57.35% |
| 2018-03-31 | $0.06B | $0.03B | 56.67% |
| 2017-12-31 | $0.05B | $0.03B | 56.86% |
| 2017-09-30 | $0.04B | $0.03B | 59.09% |
| 2017-06-30 | $0.04B | $0.02B | 56.10% |
| 2017-03-31 | $0.04B | $0.02B | 51.28% |
| 2016-12-31 | $0.04B | $0.02B | 46.15% |
| 2016-09-30 | $0.04B | $0.02B | 40.54% |
| 2016-06-30 | $0.04B | $0.01B | 34.29% |
| 2016-03-31 | $0.04B | $0.01B | 28.57% |
| 2015-12-31 | $0.04B | $0.01B | 28.57% |
| 2015-09-30 | $0.04B | $0.01B | 28.57% |
| 2015-06-30 | $0.04B | $0.01B | 35.14% |
| 2015-03-31 | $0.04B | $0.02B | 40.54% |
| 2014-12-31 | $0.04B | $0.02B | 43.24% |
| 2014-09-30 | $0.04B | $0.02B | 47.22% |
| 2014-06-30 | $0.04B | $0.02B | 43.24% |
| 2014-03-31 | $0.04B | $0.02B | 42.11% |
| 2013-12-31 | $0.04B | $0.02B | 42.50% |
| 2013-09-30 | $0.04B | $0.02B | 42.86% |
| 2013-06-30 | $0.04B | $0.02B | 46.15% |
| 2013-03-31 | $0.04B | $0.02B | 47.37% |
| 2012-12-31 | $0.04B | $0.02B | 43.24% |
| 2012-09-30 | $0.04B | $0.02B | 41.67% |
| 2012-06-30 | $0.04B | $0.02B | 43.24% |
| 2012-03-31 | $0.04B | $0.02B | 42.86% |
| 2011-12-31 | $0.03B | $0.02B | 45.45% |
| 2011-09-30 | $0.03B | $0.01B | 48.28% |
| 2011-06-30 | $0.03B | $0.01B | 48.00% |
| 2011-03-31 | $0.02B | $0.01B | 50.00% |
| 2010-12-31 | $0.02B | $0.01B | 52.17% |
| 2010-09-30 | $0.02B | $0.01B | 50.00% |
| 2010-06-30 | $0.02B | $0.01B | 40.91% |
| 2010-03-31 | $0.02B | $0.01B | 40.00% |
| 2009-12-31 | $0.02B | $0.01B | 35.29% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.360B | $0.156B |
| Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $221.767B | 27.38 |
| Boston Scientific (BSX) | United States | $151.377B | 43.52 |
| Stryker (SYK) | United States | $149.082B | 32.08 |
| EssilorLuxottica (ESLOY) | France | $125.055B | 0.00 |
| Medtronic (MDT) | Ireland | $117.214B | 17.41 |
| Lonza Group Ag (LZAGY) | Switzerland | $45.950B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.139B | 28.03 |
| GE HealthCare Technologies (GEHC) | United States | $40.136B | 20.82 |
| ResMed (RMD) | United States | $37.119B | 30.50 |
| Terumo (TRUMY) | Japan | $28.886B | 41.07 |
| Koninklijke Philips (PHG) | Netherlands | $25.642B | 19.63 |
| Zimmer Biomet Holdings (ZBH) | United States | $22.107B | 14.07 |
| Insulet (PODD) | United States | $19.438B | 77.40 |
| Baxter (BAX) | United States | $16.737B | 10.89 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.065B | 0.00 |
| BellRing Brands (BRBR) | United States | $10.084B | 40.57 |
| Sunny Optical Technology (SNPTF) | China | $9.976B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.966B | 33.87 |
| Demant (WILYY) | Denmark | $8.735B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.433B | 14.95 |
| ICU Medical (ICUI) | United States | $4.121B | 39.23 |
| Prestige Consumer Healthcare (PBH) | United States | $3.893B | 19.36 |
| Envista Holdings (NVST) | United States | $3.678B | 27.40 |
| Haemonetics (HAE) | United States | $3.430B | 16.74 |
| Perrigo (PRGO) | Ireland | $3.366B | 9.91 |
| GN Store Nord (GNNDY) | Denmark | $3.027B | 19.41 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $2.989B | 0.00 |
| QuidelOrtho (QDEL) | United States | $2.927B | 18.84 |
| Neogen (NEOG) | United States | $2.495B | 28.75 |
| LeMaitre Vascular (LMAT) | United States | $2.247B | 54.60 |
| AtriCure (ATRC) | United States | $2.067B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.464B | 25.63 |
| InMode (INMD) | Israel | $1.462B | 8.79 |
| AdaptHealth (AHCO) | United States | $1.430B | 10.22 |
| BioLife Solutions (BLFS) | United States | $1.313B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.270B | 0.00 |
| Owens & Minor (OMI) | United States | $1.150B | 8.99 |
| Evolus (EOLS) | United States | $0.922B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.887B | 15.64 |
| CeriBell (CBLL) | United States | $0.833B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.830B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.649B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.561B | 24.73 |
| Surmodics (SRDX) | United States | $0.511B | 0.00 |
| Omeros (OMER) | United States | $0.502B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.432B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.429B | 0.00 |
| Valneva SE (VALN) | France | $0.412B | 0.00 |
| ZimVie (ZIMV) | United States | $0.401B | 33.77 |
| Quanterix (QTRX) | United States | $0.370B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.322B | 30.67 |
| Sanara MedTech (SMTI) | United States | $0.317B | 0.00 |
| Biote (BTMD) | United States | $0.309B | 6.76 |
| OraSure Technologies (OSUR) | United States | $0.291B | 19.50 |
| Canopy Growth (CGC) | Canada | $0.265B | 0.00 |
| Zynex (ZYXI) | United States | $0.263B | 55.13 |
| High Tide (HITI) | Canada | $0.239B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.233B | 3.28 |
| Utah Medical Products (UTMD) | United States | $0.208B | 15.52 |
| Aurora Cannabis (ACB) | Canada | $0.203B | 0.00 |
| Brainsway (BWAY) | Israel | $0.197B | 104.70 |
| MacroGenics (MGNX) | United States | $0.190B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.189B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.154B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.149B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.145B | 18.27 |
| Quipt Home Medical (QIPT) | United States | $0.135B | 0.00 |
| Jin Medical (ZJYL) | China | $0.125B | 0.00 |
| Fonar (FONR) | United States | $0.102B | 11.54 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.091B | 0.00 |
| Veru (VERU) | United States | $0.089B | 0.00 |
| InterCure (INCR) | Israel | $0.077B | 0.00 |
| Exagen (XGN) | United States | $0.072B | 0.00 |
| INLIF (INLF) | $0.071B | 0.00 | |
| Rockwell Medical (RMTI) | United States | $0.066B | 34.00 |
| Jushi Holdings (JUSHF) | United States | $0.059B | 0.00 |
| Apyx Medical (APYX) | United States | $0.055B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.055B | 0.00 |
| Modular Medical (MODD) | United States | $0.051B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.051B | 0.00 |
| United-Guardian (UG) | United States | $0.050B | 14.35 |
| ImmuCell (ICCC) | United States | $0.048B | 0.00 |
| Safety Shot (SHOT) | United States | $0.031B | 0.00 |
| Nephros (NEPH) | United States | $0.018B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.015B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.013B | 0.00 |
| Flora Growth (FLGC) | United States | $0.011B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.010B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Agape ATP (ATPC) | $0.005B | 0.00 | |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.001B | 0.00 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |